Clinical trials
Recent articles
Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory
A new review of 15 years of studies on the connection between the microbiome and autism reveals widespread statistical and conceptual errors.
Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory
A new review of 15 years of studies on the connection between the microbiome and autism reveals widespread statistical and conceptual errors.
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
Why hype for autism stem cell therapies continues despite dead ends
After numerous tests, there is still no evidence that these experimental treatments help, so now is not the time to expand access to them.
Why hype for autism stem cell therapies continues despite dead ends
After numerous tests, there is still no evidence that these experimental treatments help, so now is not the time to expand access to them.
Expediting clinical trials for profound autism: Q&A with Matthew State
Aligning Research to Impact Autism, a new initiative funded by the Sergey Brin Family Foundation, wants to bring basic science discoveries to the clinic faster.
Expediting clinical trials for profound autism: Q&A with Matthew State
Aligning Research to Impact Autism, a new initiative funded by the Sergey Brin Family Foundation, wants to bring basic science discoveries to the clinic faster.
What’s next for brain-directed gene therapy after death in Neurogene trial
The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.
What’s next for brain-directed gene therapy after death in Neurogene trial
The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Leveraging the power of community to strengthen clinical trials for rare genetic syndromes
Families can become not only participants but champions of these research efforts.
Leveraging the power of community to strengthen clinical trials for rare genetic syndromes
Families can become not only participants but champions of these research efforts.
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
The facility’s institutional review board failed to report a 2021 incident and “serious and ongoing noncompliance” by a principal investigator, according to a letter released by the federal agency this week.
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
The facility’s institutional review board failed to report a 2021 incident and “serious and ongoing noncompliance” by a principal investigator, according to a letter released by the federal agency this week.
Seen and heard: The Transmitter’s top multimedia stories in 2023
Our audio, video and photo highlights from the past year help to transport readers into scientists’ lives and research, and the lives of their study participants.
Seen and heard: The Transmitter’s top multimedia stories in 2023
Our audio, video and photo highlights from the past year help to transport readers into scientists’ lives and research, and the lives of their study participants.
Explore more from The Transmitter
Psychedelics research in rodents has a behavior problem
Simple behavioral assays—originally validated as drug-screening tools—fall short in studies that aim to unpack the psychedelic mechanism of action, so some behavioral neuroscientists are developing more nuanced tasks.
Psychedelics research in rodents has a behavior problem
Simple behavioral assays—originally validated as drug-screening tools—fall short in studies that aim to unpack the psychedelic mechanism of action, so some behavioral neuroscientists are developing more nuanced tasks.
New organoid atlas unveils four neurodevelopmental signatures
The comprehensive resource details data on microcephaly, polymicrogyria, epilepsy and intellectual disability from 352 people.
New organoid atlas unveils four neurodevelopmental signatures
The comprehensive resource details data on microcephaly, polymicrogyria, epilepsy and intellectual disability from 352 people.
Can neuroscientists decode memories solely from a map of synaptic connections?
Five experts discuss the progress, possibilities and hurdles of decoding a “nontrivial” memory from an organism just by analyzing its brain connectivity patterns.
Can neuroscientists decode memories solely from a map of synaptic connections?
Five experts discuss the progress, possibilities and hurdles of decoding a “nontrivial” memory from an organism just by analyzing its brain connectivity patterns.